12/18
08:30 am
tem
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
High
Report
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
12/17
08:45 am
tem
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device [Yahoo! Finance]
Medium
Report
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device [Yahoo! Finance]
12/17
08:45 am
tem
Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis
Medium
Report
Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis
12/17
08:30 am
tem
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
Low
Report
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
12/13
11:16 am
tem
Tempus AI, Inc. (NASDAQ: TEM) had its price target raised by analysts at Bank of America Co. from $52.00 to $54.00. They now have a "neutral" rating on the stock.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) had its price target raised by analysts at Bank of America Co. from $52.00 to $54.00. They now have a "neutral" rating on the stock.
12/13
09:03 am
tem
Tempus AI, Inc. (NASDAQ: TEM) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $60.00 price target on the stock.
Low
Report
Tempus AI, Inc. (NASDAQ: TEM) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $60.00 price target on the stock.
12/9
08:11 am
tem
Tempus AI, Inc. (NASDAQ: TEM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $74.00 price target on the stock.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $74.00 price target on the stock.
11/25
02:40 pm
tem
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects? [Yahoo! Finance]
Medium
Report
Will Ambry Genetics Acquisition Drive Tempus AI's Prospects? [Yahoo! Finance]
11/25
08:30 am
tem
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/12
11:33 am
tem
Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) had its "neutral" rating re-affirmed by analysts at Piper Sandler. They now have a $70.00 price target on the stock, up previously from $40.00.
11/12
08:30 am
tem
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
Medium
Report
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
11/11
08:30 am
tem
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
Medium
Report
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
11/11
08:08 am
tem
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.
Medium
Report
Tempus AI, Inc. (NASDAQ: TEM) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $65.00 price target on the stock, up previously from $45.00.
11/9
05:11 am
tem
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/8
08:30 am
tem
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
High
Report
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
11/7
06:09 pm
tem
Tempus AI Inc (NASDAQ:TEM) Continues Strong Growth with 33% Revenue Increase, Price Target Raised to $56 [Yahoo! Finance]
High
Report
Tempus AI Inc (NASDAQ:TEM) Continues Strong Growth with 33% Revenue Increase, Price Target Raised to $56 [Yahoo! Finance]
11/7
04:47 pm
tem
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test [Yahoo! Finance]
High
Report
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test [Yahoo! Finance]
11/7
04:30 pm
tem
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
High
Report
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
11/7
08:38 am
tem
Exciting Growth Potential Ahead for Tempus AI (TEM) [Yahoo! Finance]
Low
Report
Exciting Growth Potential Ahead for Tempus AI (TEM) [Yahoo! Finance]
11/5
12:13 pm
tem
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates [Yahoo! Finance]
11/5
02:27 am
tem
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
Medium
Report
Tempus AI Inc (TEM) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... [Yahoo! Finance]
11/4
04:45 pm
tem
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics [Yahoo! Finance]
Medium
Report
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics [Yahoo! Finance]
11/4
04:01 pm
tem
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
Medium
Report
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
11/3
08:06 pm
tem
Tempus to Report Third Quarter 2024 Financial Results on November 4
Medium
Report
Tempus to Report Third Quarter 2024 Financial Results on November 4
10/24
08:30 am
tem
Tempus to Report Third Quarter 2024 Financial Results on November 7
Low
Report
Tempus to Report Third Quarter 2024 Financial Results on November 7